Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative donafenib + PD-1 antibody with or without HAIC versus postoperative adjuvant donafenib + PD-1 in resectable high-risk hepatocellular carcinoma
ChiCTR2300074183Phase 4Not yet recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Aug 2023
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of donafenib and PD-1 Monoclonal Antibody in hepatocellular carcinoma (HCC) (2 arms), sponsored by Chinese PLA General Hospital. Primary endpoint: 1-year recurrence-free rate. Planned start Aug 2023; status: not yet recruiting.
02
Drugs
donafenibPD-1 Monoclonal Antibody
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2300074183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300074183.